Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors.

Contemporary clinical trials·2020

Same author

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.

Journal of Alzheimer's disease : JAD·2020

Same author

Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2020

Same author

The genetic architecture of human brainstem structures and their involvement in common brain disorders.

Nature communications·2020

Same author

An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene.

Neurobiology of aging·2020

Same author

Antidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort.

Journal of the American Medical Directors Association·2020

Search research articles

Related Experiment Video

Updated: May 30, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

Clinical trials on sarcopenia: methodological issues regarding phase 3 trials.

Gabor Abellan van Kan¹, Wm Cameron Chumlea, Sophie Gillette-Guyonet

¹Gérontopôle, Department of Geriatric Medicine, Toulouse University Hospital, France. abellan-van-kan-g@chu-toulouse.fr

Clinics in Geriatric Medicine

|August 10, 2011

Summary

Phase 3 trials are crucial for evaluating interventions to prevent, delay, or treat sarcopenia in at-risk individuals. Addressing challenges in elderly participants is key to developing strategies against age-related muscle loss and disability.

Related Experiment Videos

Last Updated: May 30, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

Area of Science:

Gerontology
Clinical Trials
Muscle Physiology

Background:

Sarcopenia, age-related muscle loss, significantly impacts elderly health and mobility.
Effective interventions are needed to prevent, delay, or treat sarcopenia and mitigate associated disability.

Purpose of the Study:

To outline the critical considerations for designing and conducting Phase 3 clinical trials for sarcopenia interventions.
To address key issues including definition, target population, endpoints, trial duration, and assessment methods.

Main Methods:

Focus on Phase 3 trial design for sarcopenia interventions.
Emphasizes participant selection (sarcopenia or risk profile) and control group standards (best clinical care).
Discusses crucial trial elements: definition, population, endpoints, duration, muscle/strength/performance assessment, and confounder control.

Main Results:

Phase 3 trials are essential for validating sarcopenia interventions.
Standardized methodologies for muscle mass, strength, and physical performance assessment are vital.
Careful control of confounders is necessary for reliable results.

Conclusions:

Despite challenges in elderly populations, Phase 3 trials offer opportunities to develop effective sarcopenia countermeasures.
Successful trials can lead to new strategies to combat age-related muscle decline and prevent late-life disability.